Armstrong Advisory Group’s Cue Biopharma CUE Stock Holding History

Armstrong Advisory Group’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4	Closed	-$28	–	990
2026 Q1	$28	Hold	4	–	–	﹤0.01%	956
2025 Q4	$37	Hold	4	–	–	﹤0.01%	951
2025 Q3	$87	Hold	4	–	–	﹤0.01%	933
2025 Q2	$82	Hold	4	–	–	﹤0.01%	919
2025 Q1	$131	Hold	4	–	–	﹤0.01%	833
2024 Q4	$131	Hold	4	–	–	﹤0.01%	833
2024 Q3	$91	Hold	4	–	–	﹤0.01%	778
2024 Q2	$149	Hold	4	–	–	﹤0.01%	785
2024 Q1	$317	Hold	4	–	–	﹤0.01%	757
2023 Q4	$317	Hold	4	–	–	﹤0.01%	757
2023 Q3	$276	Hold	4	–	–	﹤0.01%	824
2023 Q2	$438	Hold	4	–	–	﹤0.01%	782
2023 Q1	$429	Hold	4	–	–	﹤0.01%	763
2022 Q4	$342	Buy	+4	New	+$366	﹤0.01%	793

Other funds holding CUE

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

AWM

Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Armstrong Advisory Group's CUE Position: Q2 2026 in Review

Armstrong Advisory Group sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 4 shares — an estimated $28 sold.

Armstrong Advisory Group first reported a position in CUE in Q4 2022 and held it in 14 quarters. The position peaked at $438 in Q2 2023. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

Armstrong Advisory Group reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
Armstrong Advisory Group sold 4 Cue Biopharma shares in Q2 2026, an estimated $28.
Armstrong Advisory Group first reported a position in Cue Biopharma in Q4 2022 and held it in 14 quarters.
Armstrong Advisory Group's Cue Biopharma position peaked at $438 in Q2 2023.
8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.